Defibrillator Manufacturing in the US: Market Size, Businesses & Forecast 2026

The U.S. defibrillator manufacturing sector comprises establishments that design, engineer, and manufacture life-saving cardiac resuscitation devices, including Automated External Defibrillators (AEDs), Implantable Cardioverter-Defibrillators (ICDs), and advanced professional defibrillator-monitors. Classified under the broader electromedical apparatus sector, the industry output contributed to a total subsector shipment value of 35.5 billion USD in 2020 (U.S. Census Bureau Annual Survey of Manufactures). Driven by rising cardiovascular disease prevalence, expanding public-access CPR/AED legislation, and technological innovations in wearable and subcutaneous devices, the industry exhibits st

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Defibrillator Manufacturing in the US industry cover?

Defibrillator manufacturing encompasses the research, design, production, and quality testing of electronic medical devices designed to treat lethal cardiac dysrhythmias such as ventricular fibrillation and pulseless ventricular tachycardia. Products manufactured within this sector fall into three primary categories: implantable cardioverter-defibrillators (ICDs), wearable cardioverter-defibrillators (WCDs), and external defibrillators, which include automated external defibrillators (AEDs) and advanced manual defibrillators used by emergency medical services (EMS) and hospitals. The primary manufacturing processes involve microelectronics assembly, precision software coding, biocompatible casing encapsulation, high-voltage capacitor testing, and strict environmental batch sampling.

• •Primary NAICS classification: 334510 (Electromedical and Electrotherapeutic Apparatus Manufacturing).
• •Covers implantable devices (transvenous and subcutaneous ICDs), public-access AEDs, and clinical defibrillator-monitors.
• •Regulated primarily under FDA 21 CFR Part 820 Quality System Regulation (QSR) and FDA Medical Device Amendments.

Who operates in the industry and how is it structured?

The U.S. defibrillator manufacturing market is highly concentrated and capital-intensive, characterized by high barriers to entry due to stringent regulatory compliance and substantial research and development investment requirements. Production is led by a select group of major multinational medical technology corporations that operate domestic manufacturing, assembly, and clinical engineering facilities across key life-sciences hubs in Minnesota, Massachusetts, California, and Washington. These operators supply hospitals, pre-hospital EMS agencies, commercial establishments, government agencies, and consumer markets through specialized direct sales forces and medical supply distributors.

• •High barrier to entry due to multi-year FDA Premarket Approval (PMA) pathways and intellectual property portfolios.
• •Geographic concentration of manufacturing operations in Minnesota, Massachusetts, California, and Washington.
• •Distribution relies on direct enterprise contracts with health systems, municipalities, and commercial distributors.

What drives demand in the industry?

Demand for defibrillators in the United States is fundamentally driven by the high incidence of sudden cardiac arrest (SCA) and ischemic heart disease among an aging domestic population. Institutional demand is further reinforced by state and federal public-access defibrillation laws requiring AED installation in schools, airports, federal buildings, and athletic facilities. Additionally, advancements in electrophysiology, such as extravascular and subcutaneous ICD technologies, expand clinical indications and drive replacement cycles for legacy devices.

• •Cardiovascular disease remains the leading cause of death in the United States according to CDC data.
• •Expanding municipal and state legislative mandates requiring public-access AED placement in high-density facilities.
• •Increased clinical adoption of subcutaneous and wearable defibrillation solutions for high-risk cardiac patients.

Who are the notable companies in the industry?

Competition in the U.S. defibrillator sector centers on device reliability, battery life, remote monitoring capabilities, ease of use for lay responders, and clinical efficacy data. The market is led by established public medical device companies and specialized subsidiaries of international technology conglomerates. Major companies maintain significant U.S. operational facilities dedicated to electrophysiology research, software engineering, and cleanroom manufacturing.

• •Medtronic plc: Manufactures transvenous and extravascular ICD systems with operational headquarters in Minneapolis, Minnesota.
• •Boston Scientific Corporation: Produces subcutaneous implantable cardioverter-defibrillators (S-ICD) and cardiac rhythm management systems.
• •Stryker Corporation: Manufactures LIFEPAK external defibrillators and CR2 AED systems via its Emergency Care division.
• •Koninklijke Philips N.V.: Supplies HeartStart series AEDs and clinical defibrillator-monitors to public and hospital sectors.

What are the recent trends and outlook?

Recent technological advancements in defibrillator manufacturing emphasize cloud connectivity, cellular telemetry, and artificial intelligence algorithms for real-time ECG analysis and remote patient monitoring. Manufacturing processes increasingly incorporate automated optical inspection and rigorous microelectronics testing to eliminate hardware defect risks prior to clinical deployment. Future industry outlook remains positive as next-generation subcutaneous devices and ultra-portable public-access AEDs continue to gain regulatory approval and market adoption.

• •Integration of wireless cellular communication and cloud portal platforms for automated AED status monitoring.
• •Regulatory transition of all external defibrillators from 510(k) clearance to Premarket Approval (PMA) status under FDA mandates.
• •Growth in wearable and minimally invasive extravascular ICD platforms that avoid transvenous lead placement.

How is the industry regulated?

Defibrillators are classified as Class III (high-risk) life-sustaining medical devices by the U.S. Food and Drug Administration (FDA). Manufacturers are subject to rigorous oversight, requiring Premarket Approval (PMA) applications supported by extensive clinical trial data before commercial release. Post-market compliance mandates continuous adverse event reporting through the FDA Medical Device Reporting (MDR) system, adherence to 21 CFR Part 820 Quality System Regulations, and periodic FDA facility audits.

• •Regulated under FDA Class III medical device rules requiring full Premarket Approval (PMA) submissions.
• •Mandatory adherence to FDA Quality System Regulation (21 CFR Part 820) and ISO 13485 quality standards.
• •Strict post-market surveillance, recall tracking, and Medical Device Reporting (MDR) under 21 CFR Part 803.

Government, statistical and trade sources used for this Claight analysis.

• U.S. Census Bureau Annual Survey of Manufactures 2020 ·
• U.S. International Trade Administration Medical Devices Report 2022 ·
• U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health 2023 ·
• U.S. Office of Management and Budget NAICS Manual 2022